Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06421935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial status: Recruiting to Active, Not RecruitingSite details revised at 20 of 20 sitesv18Show 1 more changeShow less
Site details revised at 20 of 20 sites
Minor2 versionsRe-verified since Oct 16, 2025, no change to tracked fieldsv16-v17
Show 14 earlier versionsHide 14 earlier versions
MinorStudy sites: 19 to 20v15
NotablePrimary completion date: Mar 9, 2026 to Feb 22, 2027Primary endpoints: 5 to 6 · Enrollment target: 96 to 141 · Completion date: Mar 26, 2026 to Feb 22, 2027 · 2 morev14Show 5 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 2 to 1 · Start date: Aug 2, 2024 to Aug 7, 2024v3Show 2 more changesShow less
Study sites: 2 to 1
Start date: Aug 2, 2024 to Aug 7, 2024
NotableStart date: Jul 1, 2024 to Aug 2, 2024v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.